BioSpyder Secures 5-Year TempO-Seq Supply Agreement with Health Canada

BioSpyder Technologies, Inc. has signed a five-year contract with Health Canada to provide transcriptomics kits powered by its proprietary TempO-Seq™ assay technology. This long-term agreement highlights BioSpyder’s growing role as a trusted supplier for government agencies worldwide seeking reliable, scalable, and cost-effective solutions for genetic research and toxicology screening. 

Under the terms of the agreement, BioSpyder will deliver its high-throughput TempO-Seq assays to support Health Canada’s mission to better understand chemical, environmental, and health-related impacts on diverse biological systems. This further establishes TempO-Seq as a leading molecular profiling tool, valued for its ability to deliver robust results faster, cheaper, and better than traditional RNA sequencing approaches. 

“Working with Health Canada is important in our mission to make advanced transcriptomics accessible to scientists and regulators around the world,” said Garrett McComb, Director of BioSpyder Technologies. “TempO-Seq has already proven its ability to accelerate decision-making by removing bottlenecks in sample prep and data collection. This contract reflects the confidence placed in our platform and underscores its potential to shape the future of global health and environmental safety initiatives.”